Last reviewed · How we verify

Cytomel (Liothyronine Sodium)

Pfizer Inc. · FDA-approved approved Small molecule Verified Quality 72/100

Thyroid hormones bind nuclear receptors to control DNA transcription and protein synthesis.

Liothyronine sodium (Cytomel) is a synthetic T3 thyroid hormone indicated for hypothyroidism replacement, TSH suppression in thyroid cancer management, and diagnostic thyroid suppression testing. The drug is rapidly absorbed (95% in 4 hours) with a 2.5-day half-life and works by binding nuclear thyroid receptors to regulate gene transcription. Major risks include hyperthyroidism from overdosage causing cardiac arrhythmias, myocardial infarction, and tremors, plus contraindication in uncorrected adrenal insufficiency. Multiple drug interactions affect absorption and protein binding, requiring careful monitoring and dosing adjustments.

At a glance

Generic nameLiothyronine Sodium
SponsorPfizer Inc.
Drug classThyroid hormone replacement
TargetThyroid receptor proteins attached to DNA
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Mechanism of action

Liothyronine sodium (T3) is a synthetic thyroid hormone that diffuses into cell nuclei and binds to thyroid receptor proteins attached to DNA. This hormone-receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, with approximately 80% of circulating T3 derived from T4 by deiodination in peripheral tissues.

Approved indications

Boxed warnings

Common side effects

Serious adverse events

Drug interactions